SCHEMBL10116482

SCHEMBL10116482

CC1CN(c2ccc(NC(=O)C3CCC(NS(=O)(=O)C(C)C)CC3)cc2Cl)C[C@@H](C)O1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.48
ALDH1A1 P00352 1/20 0.48
TSHR P16473 1/20 0.48
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
NPY2R P49146 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 2/20 0.42
MALT1 Q9UDY8 1/20 0.42
LMNA P02545 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
HTT P42858 1/20 0.42
KDM4E B2RXH2 1/20 0.41
RECQL P46063 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
EPHX2 P34913 1/20 0.41
GSK3B P49841 1/20 0.41
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10114721 1.00 HPGD (0.48) HPGDALDH1A1TSHRMEN1KMT2A
SCHEMBL13204294 1.00 HPGD (0.48) HPGDALDH1A1TSHRMEN1KMT2A
SCHEMBL10133617 1.00 HPGD (0.48) HPGDALDH1A1TSHRMEN1KMT2A
SCHEMBL10114386 0.90 KDM4E (0.40) MEN1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL10114735 0.90 KDM4E (0.40) MEN1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL10114384 0.89 MAPT (0.48) MEN1KMT2ANPY2RMAPTLMNA
SCHEMBL10133387 0.89 MAPT (0.48) MEN1KMT2ANPY2RMAPTLMNA
SCHEMBL10114324 0.88 HPGD (0.49) HPGDALDH1A1TSHRMEN1KMT2A
SCHEMBL10133406 0.88 HPGD (0.49) HPGDALDH1A1TSHRMEN1KMT2A
SCHEMBL14627693 0.88 HPGD (0.49) HPGDALDH1A1TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R HPGD 3475/4885ALDH1A1 4599/4885TSHR 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.